Today news
The same in other media
08.06 - 09:09
08.06 - 07:59
05.06 - 07:23
Ajanta Pharma delivers decent Q4, but growth may be priced in
Reading now: 336
With its revenues and profits coming a step ahead of the Street’s forecasts, Ajanta Pharma Ltd’s Q4 figures have been impressive.
But business and logistics disruptions due to the lockdown may curb the growth momentum in FY21. Its US business growth has been reassuring.
US generic sales grew 88% year-on-year largely as consumers stocked up amid the covid-19 outbreak. Its higher exports, of about 43% year-on-year, is further encouraging as the company capitalises on the mounting demand.
The company's shares have run-up in the past few months on the sales momentum. In 2020 so far, the stock has jumped 50%, while it gained about 4.5% on Thursday.
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|